<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hum Reprod Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Hum Reprod Sci</journal-id><journal-id journal-id-type="publisher-id">JHRS</journal-id><journal-title-group><journal-title>Journal of Human Reproductive Sciences</journal-title></journal-title-group><issn pub-type="ppub">0974-1208</issn><issn pub-type="epub">1998-4766</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27382235</article-id><article-id pub-id-type="pmc">4915279</article-id><article-id pub-id-type="publisher-id">JHRS-9-101</article-id><article-id pub-id-type="doi">10.4103/0974-1208.183506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: A prospective randomized study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mahajan</surname><given-names>Nalini</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shilpa</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Arora</surname><given-names>Puneet Rana</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Shalu</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rani</surname><given-names>Kumkum</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Naidu</surname><given-names>Padmaja</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Reproductive Medicine, Nova IVI Fertility, New Delhi, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Nalini Mahajan, Nova IVI Fertility, B-2/1 A Safdarjang Enclave, Africa Avenue, New Delhi - 110 029, India. E-mail: <email xlink:href="dr.nalinimahajan@gmail.com">dr.nalinimahajan@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2016</year></pub-date><volume>9</volume><issue>2</issue><fpage>101</fpage><lpage>106</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2015</year></date><date date-type="rev-recd"><day>28</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Human Reproductive Sciences</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>BACKGROUND:</title><p>Mature oocytes are prerequisite for achieving the process of <italic>in vitro</italic> fertilization. Human chorionic gonadotropin (hCG) is the standard trigger used for stimulating ovulation but is associated with ovarian hyperstimulation syndrome (OHSS). Gonadotropin-releasing hormone agonist trigger achieves oocyte maturation and lowers the incidence of OHSS, but it has limitations of higher pregnancy loss rate and miscarriage rates. Coadministration of both hormones is found to improve the pregnancy rates and the number of mature oocytes retrieved. We aimed to assess if the dual trigger is better than the conventional hCG in triggering oocyte maturation.</p></sec><sec id="st2"><title>METHODOLOGY:</title><p>The study included 76 female patients aged 24&#x02013;43 years who were randomly divided into two groups with 38 patients in each arm. The study included patients with antimullerian hormone (AMH) &#x0003c;4 ng/ml, antral follicle counts (AFCs)/ovary &#x0003c;12. The study excluded high responders-AMH &#x0003e;4 ng/ml and AFC/ovary &#x0003e;12 to avoid OHSS risk with hCG trigger.</p></sec><sec id="st3"><title>RESULTS:</title><p>The study showed statistically insignificant differences between dual group versus hCG group in terms of the number of oocytes retrieved (10.0 &#x000b1; 5.6 vs. 8.7 &#x000b1; 5.0; <italic>P</italic> = 0.2816), the number of mature oocytes recovered (8.4 &#x000b1; 5.0 vs. 7.2 &#x000b1; 4.0; <italic>P</italic> = 0.2588), fertilization rate (5.9 &#x000b1; 4.2 vs. 5.6 &#x000b1; 3.3; <italic>P</italic> = 0.7390), and the number of usable embryos on day 3 (4.0 &#x000b1; 3.0 vs. 4.0 &#x000b1; 2.4; <italic>P</italic> = 0.8991).</p></sec><sec id="st4"><title>CONCLUSION:</title><p>The dual trigger is equivalent to hCG in triggering oocyte maturation.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Dual trigger</kwd><kwd>gonadotropin-releasing hormone agonist trigger</kwd><kwd>oocyte maturation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>The follicular phase of the menstrual cycle involves the hourly release of gonadotropin-releasing hormone (GnRH), which binds to GnRH receptors on the gonadotropes. This results in the secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in hourly pulses that regulate follicular growth. At midcycle, rapidly rising estradiol from the dominant follicle and a small rise in progesterone (P) lead to a gonadotrophic surge. An increase in the amplitude of LH and FSH pulses initiates oocyte maturity and triggers ovulation approximately 36&#x02013;40 h later.[<xref rid="ref1" ref-type="bibr">1</xref>]</p><p>Because of its similarity to LH and its long half-life &#x0003e;24 h,[<xref rid="ref2" ref-type="bibr">2</xref>] human chorionic gonadotropin (hCG) has been used traditionally to trigger ovulation. In 1973, Nakano <italic>et al</italic>. showed that a bolus of GnRH agonist (GnRHa) given intravenously could induce the LH surge.[<xref rid="ref3" ref-type="bibr">3</xref>] Subsequently, various authors confirmed that ovulation could be achieved successfully when a small bolus of GnRHa was given subcutaneously (s/c).[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] GnRHa trigger induces final maturation of follicles through an endogenous surge of LH and FSH, which closely resembles the natural midcycle surge. The additional FSH surge induced is believed to promote the resumption of oocyte meiosis, LH receptor formation, cumulus expansion, and release of proteolytic enzymes involved in ovulation.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] GnRHa trigger has been demonstrated to result in the retrieval of a higher number of mature oocytes as compared with hCG;[<xref rid="ref9" ref-type="bibr">9</xref>] furthermore, it is believed to eliminate the risk of ovarian hyperstimulation syndrome (OHSS).[<xref rid="ref10" ref-type="bibr">10</xref>] However, the use of GnRHa alone as a trigger results in a lower pregnancy rate and an extremely high early pregnancy loss rate due to a luteal phase insufficiency.[<xref rid="ref11" ref-type="bibr">11</xref>]</p><p>Studies attempted to test the concept of the dual trigger, which involves combining GnRHa with a low dose of hCG to trigger oocyte maturation.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] It was proposed that dual trigger approach provided better oocyte maturity, blastulation rates, and pregnancy rates.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref18" ref-type="bibr">18</xref>]</p><p>Our study attempted to assess if the dual trigger is more efficacious than the conventionally used hCG in obtaining a higher number of mature oocytes and usable day 3 embryos.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODOLOGY</title><sec id="sec2-1"><title>Study population</title><p>The study included 76 female patients aged 24&#x02013;43 years with antimullerian hormone (AMH) &#x0003c;4 ng/ml, antral follicle counts (AFCs)/ovary &#x0003c;12 and those ready to sign an informed consent. The study excluded high responders-AMH &#x0003e;4 ng/ml and AFC/ovary &#x0003e;12 to avoid OHSS risk with hCG trigger.</p></sec><sec id="sec2-2"><title>Ethical statement</title><p>This randomized prospective pilot study was conducted at an infertility center. The study was approved by an Independent Ethics Committee. All the patients provided written informed consent before their enrollment in the study. The study followed good clinical practices as required by the International Conference on Harmonization guidelines, the ethical guidelines for biomedical research on human subjects (ICMR, 2006), and the Declaration of Helsinki.[<xref rid="ref19" ref-type="bibr">19</xref>]</p></sec><sec id="sec2-3"><title>Dosage schedule</title><p>An antagonist protocol with gonadotropin stimulation was used. Starting dose of gonadotropin was based on age, AMH, AFC, and body mass index (BMI).</p><p>A combination of recombinant FSH GONAL-f (Merck Serono) for first 5 days followed by Menopure (Ferring Pharmaceutical Pvt. Ltd.,) was used in all patients as per our standard protocol.</p><p>For ovulation trigger, the patients were divided into two groups: hCG group received an ovulation trigger of hCG 10,000 IU I/M (Bharat Serum and Vaccines Ltd.,) and dual group were triggered with luperide 1 mg s/c (Sun Pharmaceuticals Ltd.,) plus hCG 5000 IU (Bharat Serum and Vaccines Ltd.,) administered at the same time.</p><p>Intracytoplasmic sperm injection was performed in all the patients. Oocyte maturity and embryo grading were done as per the laboratory protocol.</p></sec><sec id="sec2-4"><title>Monitoring</title><p>Baseline estrogen (E<sub>2</sub>) level, <italic>P</italic> level, and ultrasound were done on day 2 of the cycle. Ovarian stimulation was started when all the values were normal, i.e. endometrium &#x0003c;5 mm, no follicle &#x0003e;10 mm in the ovaries, E<sub>2</sub> &#x0003c;50 pg/ml, and <italic>P</italic> &#x0003c; 0.9 ng/ml. The first monitoring was done on day 5 of stimulation. GnRH antagonist, cetrorelix (0.25 mg, s/c; Intas Pharmaceutical Ltd.,) was started in a flexible regime when the lead follicle reached 13 mm, and/or endometrial thickness was &#x0003e;6 mm &#x02013; suggesting a rising E<sub>2</sub> level. The dose of gonadotropin was adjusted as per individual requirement. Ovulation trigger was given when at least three follicles were &#x0003e;18 mm. E<sub>2</sub> and <italic>P</italic> levels were measured on the morning of the trigger. The primary outcome measure was to compare the number of Metaphase II (MII) oocytes and number of usable embryos (embryos good for transfer and cryopreservation) on day 3 in the two groups. A subgroup analysis was performed for patients with AMH &#x0003c;1.4 ng/ml.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>A total of 76 patients were randomly assigned to either the dual group (<italic>n</italic> = 38) or the control hCG group (<italic>n</italic> = 38). Simple randomization was performed using sequentially numbered sealed envelopes. The envelope was opened by our head nurse. The two groups were matched for age, BMI, basal hormone levels, and cause of infertility. The mean age of the patients in dual group versus hCG group was 32 &#x000b1; 5 years (range: 24&#x02013;42) and 33 &#x000b1; 4 years (range: 25&#x02013;43), respectively. The groups did not significantly differ with regard to the baseline characteristics such as age, BMI, basal FSH, LH, and AMH levels [<xref ref-type="table" rid="T1">Table 1</xref>]. Etiology of infertility in patients of both the groups was similar and is presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients in study group</p></caption><graphic xlink:href="JHRS-9-101-g001"/></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Etiology of infertility in dual trigger and human chorionic gonadotropin group</p></caption><graphic xlink:href="JHRS-9-101-g002"/></fig><p>The outcome of ovarian stimulation and hormonal characteristics are presented in Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>, respectively. The duration of stimulation and the average total dose of gonadotropins given to the patients did not differ between the groups compared [<xref ref-type="table" rid="T2">Table 2</xref>]. Although the average number of total oocytes retrieved (10.0 &#x000b1; 5.6 vs. 8.7 &#x000b1; 5.0; <italic>P</italic> = 0.2816) and MII oocytes (8.4 &#x000b1; 5.0 vs. 7.2 &#x000b1; 4.0; <italic>P</italic> = 0.2588) were more in the dual group as compared to hCG group, the difference was insignificant [<xref ref-type="table" rid="T2">Table 2</xref>]. The difference between outcomes of the other variables including number of two-pronuclear (2PN) zygotes (5.9 &#x000b1; 4.2 vs. 5.6 &#x000b1; 3.3; <italic>P</italic> = 0.7390) and usable embryos (4.0 &#x000b1; 3.0 vs. 4.0 &#x000b1; 2.4; <italic>P</italic> = 0.8991) also varied insignificantly among the two groups [<xref ref-type="table" rid="T2">Table 2</xref>]. There were no differences between the groups in the serum E<sub>2</sub> and <italic>P</italic> levels on the day of triggering final oocyte maturation [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Stimulation characteristics and outcome variables in the study group</p></caption><graphic xlink:href="JHRS-9-101-g003"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Hormonal data in the study group on the day of triggering final oocyte maturation</p></caption><graphic xlink:href="JHRS-9-101-g004"/></table-wrap><p>In addition, subgroup analysis was performed to assess the effect of the dual trigger on oocyte maturation and embryos quality in patients with AMH &#x0003c;1.4 ng/ml. The sub-group analysis included total of 25 patients; dual group (<italic>n</italic> = 14) and hCG group (<italic>n</italic> = 11). There were no significant differences in the baseline characteristics between the two groups [<xref ref-type="table" rid="T4">Table 4</xref>].</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Baseline characteristics of the patients in subgroup analysis</p></caption><graphic xlink:href="JHRS-9-101-g005"/></table-wrap><p>Under subgroup analysis, the comparison of outcomes revealed greater average number of total oocytes retrieved (6.5 &#x000b1; 5.2 vs. 4.2 &#x000b1; 2.9; <italic>P</italic> = 0.2009) and MII oocytes (5.5 &#x000b1; 5.1 vs. 3.7 &#x000b1; 2.6; <italic>P</italic> = 0.3045) in dual group as compared to hCG group; however, the difference was insignificant [<xref ref-type="table" rid="T5">Table 5</xref>]. No significant differences were found in the outcomes of the other variables including the number of 2PN oocytes (3.4 &#x000b1; 3.6 vs. 2.8 &#x000b1; 2.0; <italic>P</italic> = 0.6167) and usable embryos (2.6 &#x000b1; 2.7 vs. 2.5 &#x000b1; 1.8; <italic>P</italic> = 0.9783) between the two groups [<xref ref-type="table" rid="T5">Table 5</xref>]. The levels of E<sub>2</sub> and <italic>P</italic> on the day of triggering final oocyte maturation were insignificantly different between the groups [<xref ref-type="table" rid="T6">Table 6</xref>].</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Stimulation characteristics and outcome variables in the sub-group analysis</p></caption><graphic xlink:href="JHRS-9-101-g006"/></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Hormonal data in the sub-group on the day of triggering final oocyte maturation</p></caption><graphic xlink:href="JHRS-9-101-g007"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The results of this study found no significant differences in the number of oocytes retrieval between Group 1 receiving hCG and Group 2 receiving the dual trigger. Differences in fertilization rate and usable embryos on day 3 were also insignificant between the two groups. Our study results emphasize that there is no significant benefit associated with the use of a dual trigger in comparison to conventionally used hCG for increasing the number of mature oocytes and usable day 3 embryos in <italic>in vitro</italic> fertilization (IVF). Various studies in past have been conducted to compare the efficacy of hCG with GnRHa in triggering ovulation for IVF with varying results.</p><p>Kolibianakis <italic>et al</italic>. conducted a randomized study on 106 patients to compare the efficacy of hCG with GnRHa in triggering oocyte maturation. The study showed no significant differences in the proportion of MII oocytes, fertilization rates, or the number and quality of embryos transferred between the two groups. The study was suspended due to significantly lower ongoing pregnancy in the GnRHa group (odds ratio 0.11; 95% confidence interval 0.02&#x02013;0.52).[<xref rid="ref11" ref-type="bibr">11</xref>]</p><p>Humaidan <italic>et al</italic>. (2005) also compared the efficacy of GnRHa with hCG in triggering ovulation in 121 patients who were given 0.5 mg GnRHa (<italic>n</italic> = 55) or 10,000 IU of hCG (<italic>n</italic> = 67). They reported significantly more number of oocytes retrieved in GnRHa group. However, their study also revealed lower implantation and clinical pregnancy rate and a higher rate of early pregnancy loss with the use of GnRHa trigger.[<xref rid="ref20" ref-type="bibr">20</xref>] The study by Engmann <italic>et al</italic>. which compared GnRHa with hCG found no difference in terms of the proportion of mature oocytes, number of oocytes, and fertilization rate. Implantation rate, clinical pregnancy rate, and delivery rate were also similar in both the groups.[<xref rid="ref21" ref-type="bibr">21</xref>] It is now established that GnRHa trigger is associated with corpus luteum dysfunction leading to luteal phase insufficiency with an increased rate of miscarriages and a decreased pregnancy rate.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref22" ref-type="bibr">22</xref>]</p><p>Over the past few years, the use of dual trigger has gained acceptance in triggering oocyte maturation in patients undergoing IVF.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref23" ref-type="bibr">23</xref>] It has been found that the administration of hCG simultaneously with GnRHa trigger negates its luteolytic effects.[<xref rid="ref24" ref-type="bibr">24</xref>] Haas <italic>et al</italic>. suggested that coadministration of GnRHa and hCG, i.e., dual trigger can be used for final oocyte maturation in patients with low/poor oocyte yield. These patients had normal follicular development with normal E<sub>2</sub> levels with optimal hCG levels on the day of ovum pickup after hCG trigger but a poor oocyte yield.[<xref rid="ref25" ref-type="bibr">25</xref>] Beck-Fruchter <italic>et al</italic>. reported a case suffering from recurrent empty follicle syndrome who was successfully triggered with a combination of GnRHa and hCG. Improvement in oocyte recovery after dual trigger suggests that GnRHa can improve clinical outcome. Griffin <italic>et al</italic>. conducted a study to compare dual trigger with hCG alone and found improvement in the percentage of mature oocytes retrieved in the group receiving a dual trigger, but implantation, clinical, and ongoing pregnancy rates were 11.8%, 26.1%, and 17.4%, respectively. The authors speculated that lower pregnancy rates in spite of a higher number of oocytes retrieved might be due to an underlying oocyte dysfunction.[<xref rid="ref26" ref-type="bibr">26</xref>]</p><p>It has been suggested that the greater oocyte maturity reported with GnRHa might be related to the more rapid increase in serum LH after agonist trigger when compared with the rise of serum hCG level after 10,000 IU IM injection of hCG,[<xref rid="ref27" ref-type="bibr">27</xref>] the concurrent FSH surge, or possibly both.[<xref rid="ref28" ref-type="bibr">28</xref>] An increase in the number of mature oocytes recovered would theoretically improve IVF results by providing more embryos.[<xref rid="ref29" ref-type="bibr">29</xref>]</p><p>Research has shown improved oocytes maturation rates if retrieved 38 h after the hCG bolus administration.[<xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref>] The improved oocyte maturation rates in the study by Griffin <italic>et al</italic>. might have been the result of increased trigger/oocyte retrieval time. This speculates that the use of dual trigger could not be indisputably associated with improved oocyte maturation. It appears that the use of hCG alone is helpful in achieving the same number of metaphase oocytes as compared to its combined use with GnRHa.</p><p>Our study showed contrasting results to the study by Griffin <italic>et al</italic>. The dose of hCG in the dual trigger in Griffin's study varied from 5000 IU to 10,000 IU, the hCG group underwent agonist down-regulation whereas the dual trigger group was given an antagonist protocol. In our study, the dose of hCG in dual trigger was fixed to 5000 IU. The increased dosage of hCG might have favored the increase in oocyte maturation rate in the study by Griffin <italic>et al</italic>.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>A study by Lin <italic>et al</italic>. assessed the effectiveness of dual trigger as compared to conventional hCG trigger in improving live birth, clinical pregnancy, and implantation rates. This was probably due to a significantly higher number of patients with at least one embryo of excellent quality in patients of the dual trigger group. However, in this study, oocyte maturation rates were not measured.[<xref rid="ref15" ref-type="bibr">15</xref>] These study findings were not in agreement with the study by Griffin <italic>et al</italic>.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>AMH level is known to decline with age in women and is recognized as a crucial marker for the poor response to ovarian hyperstimulation in IVF.[<xref rid="ref32" ref-type="bibr">32</xref>] Lukaszuk <italic>et al</italic>., in his study, found that AMH &#x0003c;1.4 ng/ml is associated with less success rate of live birth in women undergoing IVF.[<xref rid="ref33" ref-type="bibr">33</xref>] We conducted a subgroup analysis of women with AMH &#x0003c;1.4 ng/ml who were triggered with hCG and dual trigger. We found no significant difference in the number of usable embryos in both the groups.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>There is no significant difference in the outcomes in terms of the number of mature oocytes, fertilization rate, and number of usable embryos by day 3 on using either dual trigger or hCG. The use of any kind of trigger can be based on the type of patient, for example, for a patient who is at risk of OHSS and needs to go with a fresh embryo transfer, dual trigger can be opted for as it uses a lower dose of hCG. However, future studies and research are required to confirm our findings and improve our understanding.</p><sec id="sec2-5"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-6"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge Dr. Surleen Kaur and Ms. Nitu for helping with statistics and data collection, and Knowledge Isotopes Pvt. Ltd., (<ext-link ext-link-type="uri" xlink:href="www.knowledgeisotopes.com">www.knowledgeisotopes.com</ext-link>) for medical writing support.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoff</surname><given-names>JD</given-names></name><name><surname>Quigley</surname><given-names>ME</given-names></name><name><surname>Yen</surname><given-names>SS</given-names></name></person-group><article-title>Hormonal dynamics at midcycle: A reevaluation</article-title><source>J Clin Endocrinol Metab</source><year>1983</year><volume>57</volume><fpage>792</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6411753</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damewood</surname><given-names>MD</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Zacur</surname><given-names>HA</given-names></name><name><surname>Schlaff</surname><given-names>WD</given-names></name><name><surname>Rock</surname><given-names>JA</given-names></name><name><surname>Wallach</surname><given-names>EE</given-names></name></person-group><article-title>Disappearance of exogenously administered human chorionic gonadotropin</article-title><source>Fertil Steril</source><year>1989</year><volume>52</volume><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">2776893</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>R</given-names></name><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Kotsuji</surname><given-names>F</given-names></name><name><surname>Katayama</surname><given-names>K</given-names></name><name><surname>Wshio</surname><given-names>M</given-names></name><name><surname>Tojo</surname><given-names>S</given-names></name></person-group><article-title>&#x0201c;Triggering&#x0201d; of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF)</article-title><source>Acta Obstet Gynecol Scand</source><year>1973</year><volume>52</volume><fpage>269</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">4582787</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itskovitz-Eldor</surname><given-names>J</given-names></name><name><surname>Kol</surname><given-names>S</given-names></name><name><surname>Mannaerts</surname><given-names>B</given-names></name><name><surname>Coelingh Bennink</surname><given-names>H</given-names></name></person-group><article-title>First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)</article-title><source>Hum Reprod</source><year>1998</year><volume>13</volume><fpage>294</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9557825</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonen</surname><given-names>Y</given-names></name><name><surname>Balakier</surname><given-names>H</given-names></name><name><surname>Powell</surname><given-names>W</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for <italic>in vitro</italic> fertilization</article-title><source>J Clin Endocrinol Metab</source><year>1990</year><volume>71</volume><fpage>918</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">2119392</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imoedemhe</surname><given-names>DA</given-names></name><name><surname>Sigue</surname><given-names>AB</given-names></name><name><surname>Pacpaco</surname><given-names>EL</given-names></name><name><surname>Olazo</surname><given-names>AB</given-names></name></person-group><article-title>Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for <italic>in vitro</italic> fertilization</article-title><source>Fertil Steril</source><year>1991</year><volume>55</volume><fpage>328</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">1899396</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yding Andersen</surname><given-names>C</given-names></name><name><surname>Leonardsen</surname><given-names>L</given-names></name><name><surname>Ulloa-Aguirre</surname><given-names>A</given-names></name><name><surname>Barrios-De-Tomasi</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Byskov</surname><given-names>AG</given-names></name></person-group><article-title>FSH-induced resumption of meiosis in mouse oocytes: Effect of different isoforms</article-title><source>Mol Hum Reprod</source><year>1999</year><volume>5</volume><fpage>726</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10421799</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eppig</surname><given-names>JJ</given-names></name></person-group><article-title>FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatory follicles</article-title><source>Nature</source><year>1979</year><volume>281</volume><fpage>483</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">492307</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humaidan</surname><given-names>P</given-names></name><name><surname>Kol</surname><given-names>S</given-names></name><name><surname>Papanikolaou</surname><given-names>EG</given-names></name></person-group><collab>Copenhagen GnRH Agonist Triggering Workshop Group</collab><article-title>GnRH agonist for triggering of final oocyte maturation: Time for a change of practice?</article-title><source>Hum Reprod Update</source><year>2011</year><volume>17</volume><fpage>510</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">21450755</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engmann</surname><given-names>L</given-names></name><name><surname>DiLuigi</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Nulsen</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>D</given-names></name><name><surname>Benadiva</surname><given-names>C</given-names></name></person-group><article-title>The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing <italic>in vitro</italic> fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study</article-title><source>Fertil Steril</source><year>2008</year><volume>89</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">17462639</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Schultze-Mosgau</surname><given-names>A</given-names></name><name><surname>Schroer</surname><given-names>A</given-names></name><name><surname>van Steirteghem</surname><given-names>A</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name><name><surname>Diedrich</surname><given-names>K</given-names></name><etal/></person-group><article-title>A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><fpage>2887</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15979994</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>BS</given-names></name><name><surname>Daneshmand</surname><given-names>ST</given-names></name><name><surname>Restrepo</surname><given-names>H</given-names></name><name><surname>Garner</surname><given-names>FC</given-names></name><name><surname>Aguirre</surname><given-names>M</given-names></name><name><surname>Hudson</surname><given-names>C</given-names></name></person-group><article-title>Efficacy of induced luteinizing hormone surge after &#x0201c;trigger&#x0201d; with gonadotropin-releasing hormone agonist</article-title><source>Fertil Steril</source><year>2011</year><volume>95</volume><fpage>826</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20961539</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>BS</given-names></name><name><surname>Daneshmand</surname><given-names>ST</given-names></name><name><surname>Garner</surname><given-names>FC</given-names></name><name><surname>Aguirre</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name></person-group><article-title>Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of <italic>in vitro</italic> fertilization</article-title><source>Fertil Steril</source><year>2008</year><volume>90</volume><fpage>231</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17981269</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D</given-names></name><name><surname>Benadiva</surname><given-names>C</given-names></name><name><surname>Kummer</surname><given-names>N</given-names></name><name><surname>Budinetz</surname><given-names>T</given-names></name><name><surname>Nulsen</surname><given-names>J</given-names></name><name><surname>Engmann</surname><given-names>L</given-names></name></person-group><article-title>Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders</article-title><source>Fertil Steril</source><year>2012</year><volume>97</volume><fpage>1316</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">22480822</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MH</given-names></name><name><surname>Wu</surname><given-names>FS</given-names></name><name><surname>Lee</surname><given-names>RK</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Hwu</surname><given-names>YM</given-names></name></person-group><article-title>Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles</article-title><source>Fertil Steril</source><year>2013</year><volume>100</volume><fpage>1296</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">23993928</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>MD</given-names></name><name><surname>Forman</surname><given-names>EJ</given-names></name><name><surname>Hong</surname><given-names>KH</given-names></name><name><surname>Franasiak</surname><given-names>JM</given-names></name><name><surname>Neal</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>RT</given-names></name></person-group><article-title>Dual trigger with GnRH agonist (GnRHa) and varying doses of hCG increases the blastulation rate amongst high responders</article-title><source>Fertil Steril</source><year>2014</year><volume>102</volume><fpage>220</fpage><lpage>1</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnick</surname><given-names>AP</given-names></name><name><surname>Amrane</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>EM</given-names></name><name><surname>Reichman</surname><given-names>DE</given-names></name><name><surname>Davis</surname><given-names>OK</given-names></name><name><surname>Rosenwaks</surname><given-names>Z</given-names></name></person-group><article-title>Dual trigger versus low-dose hCG for patients with high peak E2</article-title><source>Fertil Steril</source><year>2014</year><volume>102</volume><fpage>201</fpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orvieto</surname><given-names>R</given-names></name></person-group><article-title>Triggering final follicular maturation &#x02013; HCG, GnRH-agonist or both, when and to whom?</article-title><source>J Ovarian Res</source><year>2015</year><volume>8</volume><fpage>60</fpage><pub-id pub-id-type="pmid">26293447</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>SA</given-names></name></person-group><article-title>Declaration of Helsinki and protection for vulnerable research participants</article-title><source>JAMA</source><year>2014</year><volume>311</volume><fpage>1252</fpage><pub-id pub-id-type="pmid">24668113</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humaidan</surname><given-names>P</given-names></name><name><surname>Bredkjaer</surname><given-names>HE</given-names></name><name><surname>Bungum</surname><given-names>L</given-names></name><name><surname>Bungum</surname><given-names>M</given-names></name><name><surname>Gr&#x000f8;ndahl</surname><given-names>ML</given-names></name><name><surname>Westergaard</surname><given-names>L</given-names></name><etal/></person-group><article-title>GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: A prospective randomized study</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><fpage>1213</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15760966</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engmann</surname><given-names>L</given-names></name><name><surname>Siano</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Nulsen</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>D</given-names></name><name><surname>Benadiva</surname><given-names>C</given-names></name></person-group><article-title>GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS</article-title><source>Reprod Biomed Online</source><year>2006</year><volume>13</volume><fpage>639</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17169172</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritts</surname><given-names>EA</given-names></name><name><surname>Atwood</surname><given-names>AK</given-names></name></person-group><article-title>Luteal phase support in infertility treatment: A meta-analysis of the randomized trials</article-title><source>Hum Reprod</source><year>2002</year><volume>17</volume><fpage>2287</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">12202415</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>JC</given-names></name><name><surname>Moreno</surname><given-names>J</given-names></name><name><surname>Dolz</surname><given-names>M</given-names></name><name><surname>Bonilla-Musoles</surname><given-names>FJ</given-names></name></person-group><article-title>Successful pregnancy following dual triggering concept (rhCG+GnRH agonist) in a patient showing repetitive inmature oocytes and empty follicle syndrome: Case report</article-title><source>J Med Cases</source><year>2013</year><volume>5</volume><fpage>221</fpage><lpage>6</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>BS</given-names></name><name><surname>Daneshmand</surname><given-names>ST</given-names></name><name><surname>Garner</surname><given-names>FC</given-names></name><name><surname>Aguirre</surname><given-names>M</given-names></name><name><surname>Hudson</surname><given-names>C</given-names></name></person-group><article-title>Comparison of &#x0201c;triggers&#x0201d; using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin</article-title><source>Fertil Steril</source><year>2011</year><volume>95</volume><fpage>2715</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21550042</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>J</given-names></name><name><surname>Zilberberg</surname><given-names>E</given-names></name><name><surname>Dar</surname><given-names>S</given-names></name><name><surname>Kedem</surname><given-names>A</given-names></name><name><surname>Machtinger</surname><given-names>R</given-names></name><name><surname>Orvieto</surname><given-names>R</given-names></name></person-group><article-title>Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles &#x02013; A preliminary report</article-title><source>J Ovarian Res</source><year>2014</year><volume>7</volume><fpage>77</fpage><pub-id pub-id-type="pmid">25296696</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>D</given-names></name><name><surname>Feinn</surname><given-names>R</given-names></name><name><surname>Engmann</surname><given-names>L</given-names></name><name><surname>Nulsen</surname><given-names>J</given-names></name><name><surname>Budinetz</surname><given-names>T</given-names></name><name><surname>Benadiva</surname><given-names>C</given-names></name></person-group><article-title>Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates</article-title><source>Fertil Steril</source><year>2014</year><volume>102</volume><fpage>405</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24842671</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Olivennes</surname><given-names>F</given-names></name><name><surname>Wramsby</surname><given-names>H</given-names></name><name><surname>Tay</surname><given-names>C</given-names></name><name><surname>Itskovitz-Eldor</surname><given-names>J</given-names></name><etal/></person-group><article-title>Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for <italic>in vitro</italic> fertilization</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>709</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11836309</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>BS</given-names></name><name><surname>Andersen</surname><given-names>CY</given-names></name></person-group><article-title>Major drawbacks and additional benefits of agonist trigger &#x02013; Not ovarian hyperstimulation syndrome related</article-title><source>Fertil Steril</source><year>2015</year><volume>103</volume><fpage>874</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25707333</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck-Fruchter</surname><given-names>R</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Lavee</surname><given-names>M</given-names></name><name><surname>Geslevich</surname><given-names>Y</given-names></name><name><surname>Shalev</surname><given-names>E</given-names></name></person-group><article-title>Empty follicle syndrome: Successful treatment in a recurrent case and review of the literature</article-title><source>Hum Reprod</source><year>2012</year><volume>27</volume><fpage>1357</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">22357773</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>WY</given-names></name><name><surname>Chung</surname><given-names>JT</given-names></name><name><surname>Chian</surname><given-names>RC</given-names></name><name><surname>Herrero</surname><given-names>B</given-names></name><name><surname>Demirtas</surname><given-names>E</given-names></name><name><surname>Elizur</surname><given-names>S</given-names></name><etal/></person-group><article-title>A 38 h interval between hCG priming and oocyte retrieval increases <italic>in vivo</italic> and <italic>in vitro</italic> oocyte maturation rate in programmed IVM cycles</article-title><source>Hum Reprod</source><year>2008</year><volume>23</volume><fpage>2010</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18556681</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Zhao</surname><given-names>LH</given-names></name><name><surname>Xue</surname><given-names>SL</given-names></name><etal/></person-group><article-title>The time interval between hCG priming and oocyte retrieval in ART program: A meta-analysis</article-title><source>J Assist Reprod Genet</source><year>2011</year><volume>28</volume><fpage>901</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">21792666</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rooij</surname><given-names>IA</given-names></name><name><surname>Broekmans</surname><given-names>FJ</given-names></name><name><surname>te Velde</surname><given-names>ER</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Bancsi</surname><given-names>LF</given-names></name><name><surname>de Jong</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Serum anti-M&#x000fc;llerian hormone levels: A novel measure of ovarian reserve</article-title><source>Hum Reprod</source><year>2002</year><volume>17</volume><fpage>3065</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12456604</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukaszuk</surname><given-names>K</given-names></name><name><surname>Liss</surname><given-names>J</given-names></name><name><surname>Kunicki</surname><given-names>M</given-names></name><name><surname>Jakiel</surname><given-names>G</given-names></name><name><surname>Wasniewski</surname><given-names>T</given-names></name><name><surname>Woclawek-Potocka</surname><given-names>I</given-names></name><etal/></person-group><article-title>Anti-M&#x000fc;llerian hormone (AMH) is a strong predictor of live birth in women undergoing assisted reproductive technology</article-title><source>Reprod Biol</source><year>2014</year><volume>14</volume><fpage>176</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">25152514</pub-id></element-citation></ref></ref-list></back></article>